Trevi Therapeutics, Inc.

Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting